hotspot -WSS

hotspot

author：leisure time 2025-09-30 20:27:10 - browse：38

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Future doctors should be trained to promote social change

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

AstraZeneca to buy developer of next

Virtual Event: March of the Biosimilars

How are insurers handling Leqembi and related scans?

UnitedHealth increases loan offers after Change Healthcare outage

Argenx readies a blockbuster opportunity with drug for autoimmune disease

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

U.K. researchers warn about biases in medical devices, algorithms

Medical records are filled with copy

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

In age of alternative facts, a scholarly course on calling out crap

Baby aspirin cuts fat buildup in liver disease patients, in small study

How one medical school became remarkably diverse

Watch the official trailer for 'Ahsoka' series

FDA approval of Sarepta Duchenne genetic therapy gives me hope

SCOTUS questions limit to govt efforts to fight misinformation

focus

Methadone treatment changes are coming. Do they go far enough?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Physicians and social media: If you see something, say something?

Antibody drugs appear effective. Now can we make enough of them?

EU fines Illumina $475 million over Grail acquisition

Grail's uphill battle for Medicare to cover its cancer screening test

entertainment

Wikipedia

hotspot

focus